Association of Specific LDL Receptor Gene Mutations With Differential Plasma Lipoprotein Response to Simvastatin in Young French Canadians With Heterozygous Familial Hypercholesterolemia
- 1 June 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 18 (6) , 1007-1012
- https://doi.org/10.1161/01.atv.18.6.1007
Abstract
—In familial hypercholesterolemia (FH), the efficacy of the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase shows considerable interindividual variation, and several genetic and environmental factors can contribute to explaining this variability. A randomized, double-blind, placebo-controlled clinical trial with simvastatin, an HMG-CoA reductase inhibitor, was conducted in 63 children and adolescents with heterozygous FH. The patients were grouped according to known LDL receptor genotype. After 6 weeks of treatment with 20 mg/d simvastatin, the mean reduction in plasma LDL cholesterol in patients with the W66G mutation (n=14) was 31%, whereas in the deletion>15 kb (n=23) and the C646Y mutation groups (n=10), it was 38% and 42%, respectively ( P <0.05). After treatment with simvastatin, HDL cholesterol levels were increased in all groups, and triglyceride concentrations were significantly reduced. Multiple regression analyses suggested that 42% of the variation of the LDL cholesterol response to simvastatin can be attributed to variation in the mutant LDL receptor locus, apolipoprotein E genotype, and body mass index, while 35% of the variation in HDL cholesterol response was explained by sex and baseline HDL cholesterol. These results show that simvastatin was an effective and well-tolerated therapy for FH in the pediatric population for all LDL receptor gene mutations. Moreover, the nature of LDL receptor gene mutations and other genetic and constitutional factors play a significant role in predicting the efficacy of simvastatin in the treatment of FH in children and adolescents.Keywords
This publication has 25 references indexed in Scilit:
- Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrationsAtherosclerosis, 1996
- Influence of genetic variability in the nondeletion LDL-receptor allele on phenotypic variation in French-Canadian familial hypercholesterolemia heterozygotes sharing a ‘null’ LDL-receptor gene defectAtherosclerosis, 1996
- Detection of a novel mutation (stop 468) in exon 10 of the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French CanadiansHuman Molecular Genetics, 1994
- Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemiaThe Lancet, 1993
- Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemiaAtherosclerosis, 1993
- Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemiaAtherosclerosis, 1990
- Common low-density lipoprotein receptor mutations in the French Canadian population.Journal of Clinical Investigation, 1990
- Homozygous familial hypercholesterolemia among French Canadians in Québec Province.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1989
- Deletion in the Gene for the Low-Density-Lipoprotein Receptor in a Majority of French Canadians with Familial HypercholesterolemiaNew England Journal of Medicine, 1987
- Abnormal in vivo metabolism of apolipoprotein E4 in humans.Journal of Clinical Investigation, 1986